The clinical study of direct oral anticoagulant drugs on regulating hypercoagulability of liver cirrhosis to improve prognosis after transjugular intrahepatic portosystemic shunts

The clinical study of direct oral anticoagulant drugs on regulating hypercoagulability of liver cirrhosis to improve portal vein thrombosis and prognosis after transjugular intrahepatic portosystemic shunts

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069862

Enrollment

Unknown

Registered

2023-03-28

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

DOACs group:Treated with DOACs after TIPS

control group:without anticoagulants after TIPS

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 75 years; 2.Diagnosed liver cirrhosis patients according to clinical manifestations, laboratory and imaging examinations, who are going to receive selective TIPs.

Exclusion criteria

Exclusion criteria: 1.TIPS failed; 2.Previous TIPS or surgical shunt; 3.Recurrent attacks of hepatic encephalopathy(more than 2 times); 4.Complicated with complete obstructive PVT or cavernous transformation of portal vein before TIPS; 5.Anticoagulant/antiplatelet drugs have been used before TIPS, or exist anticoagulant/antiplatelet contraindications; 6.PLT2 or Hb<70g/L; 7.Uncontrolled EGVB or stabilized for less than 2 weeks; 8.Complicated with Budd-Chiari syndrome, thrombophilia, blood system or other diseases that influence coagulation function(infection, acute kidney injury); 9.Child-Pugh score is greater than 10(Child-Pugh C); 10.Dysfunction of organs including heart, lung, kidney(CrCl<30ml/min) and brain; 11.Liver cancer and other malignant tumors beyond Milan criteria; 12.From high altitude area (higher than 2500 meters above the sea level); 13.Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Portal vein and branch thrombosis;	—

Secondary

Measure	Time frame
liver function tests;cirrhosis related events;	—

Countries

China

Contacts

Public ContactHao Wu

West China Hospital, Sichuan University

594264513@qq.com+86 18980601287

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026